General Prostate Cancer News

PCRI is pleased to provide general prostate cancer news items courtesy of CancerConsultants.com Inc. whose mission is “to empower patients with current information on all aspects of the management of Prostate Cancer in order to provide support and hope, as well as to facilitate informed decisions”.

---

News By Topic

Prostate Cancer - Screening/Prevention

Dogs May Be Able to Smell Prostate Cancer (6/8/2010)
Dogs may be able to smell the presence of prostate cancer in patient urine samples, according to data presented at the 2010 Annual Scientific Meeting of the American Urological Association (AUA).

Prostate Cancer and the Increased Risk of Blood Clots (4/23/2010)
Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.

Most Men with Benign Biopsy Cope Well During Prostate Cancer Testing (4/16/2010)
Approximately 80% of men with an elevated prostate-specific antigen (PSA) level who had a benign biopsy did not experience significant distress from these diagnostic procedures. These results were recently published in the British Journal of Cancer.

Avodart Reduces Risk of Biopsy-detected Prostate Cancer (4/7/2010)
Avodart® (dutasteride) appears to reduce the risk of prostate cancer as detected on biopsy among men at an increased risk of the disease and improves urinary symptoms related to benign prostatic hyperplasia (BPH), according to a study published in the New England Journal of Medicine.

Male Infertility Linked to Prostate Cancer (3/26/2010)
Infertile men have an increased risk of developing aggressive, high-grade prostate cancer compared with fertile men, according to the results of a study published in Cancer.

More Prostate Cancer - Screening/Prevention News »

Prostate Cancer - Early Stage I-II (A-B)

Study Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.

Statins May Reduce Risk of Prostate Cancer Recurrence (7/2/2010)
Statin use may reduce the risk of prostate cancer recurrence among men who have undergone a radical prostatectomy. These findings were recently published in the journal Cancer.

Watchful Waiting May Be Sufficient in Low-risk Prostate Cancer (6/30/2010)
Active surveillance—sometimes referred to as “watchful waiting”—may be acceptable treatment for low-risk prostate cancer, according to the results of a study published early online in the Journal of the National Cancer Institute.

External Beam Radiation Raises Risk of Hip Fracture in Prostate Cancer (6/8/2010)
Men treated with external beam radiation therapy for prostate cancer may have an increased risk of hip fracture, according to data presented at the 2010 Annual Scientific Meeting of the American Urological Association.

Statin Use May Lower Risk of Prostate Cancer Recurrence (6/3/2010)
It appears that, among men who have undergone radiation therapy for early prostate cancer, use of statins may lower risk of recurrence, according to a study published in the Journal of Clinical Oncology.

More Prostate Cancer - Early Stage I-II (A-B) News »

Prostate Cancer - Locally Advanced Stage III (C)

Study Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.

Addition of Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer (6/8/2010)
The addition of radiation therapy to hormone therapy reduces the risk of prostate cancer death by 43% among men with locally advanced or high-risk prostate cancer compared with hormone therapy alone, according to the results of a phase III study presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Prostate Cancer and the Increased Risk of Blood Clots (4/23/2010)
Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.

Neoadjuvant Chemotherapy for High-risk Localized Prostate Cancer Is Safe and Effective (3/19/2010)
Neoadjuvant treatment with Taxotere® (docetaxel) and Emcyt® (estramustine) for high-risk localized prostate cancer appears to be safe and produces promising responses compared with standard treatment, according to the results of a Phase III randomized study presented at the 2010 Genitourinary Cancers Symposium in San Francisco.

Addition of Androgen Deprivation Therapy Improves Survival with Locally Advanced Prostate Cancer (10/8/2009)
In men with locally advanced prostate cancer, the addition of androgen deprivation therapy to radiation therapy improves overall and progression-free survival without substantially affecting cardiovascular mortality. These results, based on close to 10 years of follow-up, were presented at a European cancer conference.

More Prostate Cancer - Locally Advanced Stage III (C) News »

Prostate Cancer - Metastatic Stage IV (D)

Study Explores Prostate Cancer Among Men with Low PSA Levels (7/30/2010)
In a large U.S. cancer database, 14% of prostate cancer diagnoses occurred among men with a prostate-specific antigen (PSA) level of 4.0 ng/mL or lower. More than half of these men had cancer that was considered “low-risk,” but roughly three-quarters were treated aggressively with radical prostatectomy or radiation therapy. These results were published in the Archives of Internal Medicine.

Denosumab More Effective Than Zometa® in Prostate Cancer Patients with Bone Metastases (6/7/2010)
Among men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Prostate Cancer and the Increased Risk of Blood Clots (4/23/2010)
Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.

Targeted Agents plus Chemotherapy Effective for Hormone-refractory Prostate Cancer (4/7/2010)
The combination of Avastin® (bevacizumab), Thalomid® (thalidomide), and Taxotere® (docetaxel) is highly active in hormone-refractory prostate cancer, according to the results of a study published early online in the Journal of Clinical Oncology.

Preliminary Results Indicate that an Investigational Vaccine May Extend Survival in Hormone-resistant Prostate Cancer (3/30/2010)
The investigational vaccine known as PROSTVAC-VF appears to significantly prolong survival in patients with metastatic hormone-resistant prostate cancer, according to the results of a Phase II study published in the Journal of Clinical Oncology.

More Prostate Cancer - Metastatic Stage IV (D) News »

Prostate Cancer - Refractory/Recurrent

Jevtana Approved for Hormone-refractory Prostate Cancer (6/21/2010)
Jevtana® (cabazitaxel), a new chemotherapy drug, was approved for use in combination with prednisone for the treatment of patients with metastatic hormone-refractory prostate cancer previously treated with a Taxotere® (docetaxel)-containing regimen.

Denosumab More Effective Than Zometa® in Prostate Cancer Patients with Bone Metastases (6/7/2010)
Among men with bone metastases from prostate cancer, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.

Provenge Approved for Advanced Prostate Cancer (4/30/2010)
Provenge® (sipuleucel-T), a type of immunotherapy, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of asymptomatic or minimally symptomatic, metastatic, hormone-refractory prostate cancer.

Investigational Drug Shows Activity in Advanced Prostate Cancer (4/26/2010)
An investigational anti-androgen drug called MDV3100 has shown encouraging anti-tumor activity in patients with progressive, metastatic, hormone-resistant prostate cancer, according to the preliminary results of a study published early online in the Lancet.

Prostate Cancer and the Increased Risk of Blood Clots (4/23/2010)
Men with prostate cancer are at a higher risk for several types of thromboembolic diseases (blood clots), with men undergoing endocrine therapy having the highest risk, according to the results of a study published in the Lancet Oncology.

More Prostate Cancer - Refractory/Recurrent News »

Copyright ©2005 CancerConsultants.com. All Rights Reserved.

General Prostate Cancer News Archives
 

Prostate Cancer Research Institute (PCRI)
 

Material provided by PCRI is intended for educational purposes for discussion with your physician and should not be considered as medical advice. Information and opinions expressed on this website are not an endorsement by PCRI for any treatment, product or service.